Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eliem Therapeutics Inc (NQ: ELYM )

3.070 -0.210 (-6.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,040
Open 3.300
Bid (Size) 3.070 (3)
Ask (Size) 3.260 (2)
Prev. Close 3.280
Today's Range 3.008 - 3.300
52wk Range 2.210 - 8.910
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
From Eliem Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga

Performance

YTD
-7.25%
-7.25%
1 Month
-15.66%
-15.66%
3 Month
+6.97%
+6.97%
6 Month
-4.66%
-4.66%
1 Year
-64.34%
-64.34%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce
Via Benzinga
Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study
Via Benzinga
Eliem Therapeutics: Q2 Earnings Insights
Via Benzinga
Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023
Via Benzinga
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
From Eliem Therapeutics, Inc.
Via Globe NewsWire
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
From Eliem Therapeutics, Inc.
Via Globe NewsWire
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
From Eliem Therapeutics, Inc.
Via Globe NewsWire
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
From Eliem Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022
Via Benzinga
Eliem Therapeutics Provides Update on Pipeline Progress
From Eliem Therapeutics, Inc.
Via Globe NewsWire
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Via Benzinga
SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Via Benzinga
Eliem Announces Updated Development Plans For Its Delayed Depression Candidate
Via Benzinga
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
Via Benzinga
SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know
Via Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.